Whitehawk Therapeutics to Participate in Upcoming Investor Conferences
Whitehawk Therapeutics (Nasdaq: WHWK), an oncology therapeutics company focused on ADC cancer treatments, has announced its upcoming participation in two major investor conferences. CEO Dave Lennon will engage in fireside chats at the Morgan Stanley Global Healthcare Conference on September 8, 2025 at 4:50 PM ET and the H.C. Wainwright Global Investment Conference on September 9, 2025 at 3:30 PM ET.
Both events will be held in New York City and will feature live webcasts accessible through Whitehawk's IR website, with replays available for approximately 30 days after the events.
Whitehawk Therapeutics (Nasdaq: WHWK), azienda biofarmaceutica focalizzata su terapie oncologiche ADC, ha annunciato la sua partecipazione a due importanti conferenze per investitori. Il CEO Dave Lennon prenderà parte a colloqui informali al Morgan Stanley Global Healthcare Conference l'8 settembre 2025 alle 16:50 ET e all'H.C. Wainwright Global Investment Conference il 9 settembre 2025 alle 15:30 ET.
Entrambi gli eventi si svolgeranno a New York City e saranno trasmessi in diretta via webcast sul sito IR di Whitehawk, con le repliche disponibili per circa 30 giorni dopo gli eventi.
Whitehawk Therapeutics (Nasdaq: WHWK), compañía de terapias oncológicas centrada en tratamientos ADC contra el cáncer, ha anunciado su próxima participación en dos importantes conferencias para inversores. El CEO Dave Lennon participará en charlas informales en la Morgan Stanley Global Healthcare Conference el 8 de septiembre de 2025 a las 4:50 PM ET y en la H.C. Wainwright Global Investment Conference el 9 de septiembre de 2025 a las 3:30 PM ET.
Ambos eventos se celebrarán en la ciudad de Nueva York y contarán con webcasts en directo accesibles a través del sitio IR de Whitehawk, con repeticiones disponibles durante aproximadamente 30 días después de los eventos.
Whitehawk Therapeutics (Nasdaq: WHWK), ADC 항암 치료에 주력하는 종양학 치료제 회사가 두 건의 주요 투자자 콘퍼런스에 참석할 예정이라고 발표했습니다. CEO 데이브 레논(Dave Lennon)은 Morgan Stanley Global Healthcare Conference에서 2025년 9월 8일 오후 4시 50분(동부시간)과 H.C. Wainwright Global Investment Conference에서 2025년 9월 9일 오후 3시 30분(동부시간)에 파이어사이드 토크 형식의 대담에 참여합니다.
두 행사는 모두 뉴욕시에서 열리며 Whitehawk의 IR(투자자관계) 웹사이트를 통해 생중계되며, 행사 종료 후 약 30일간 다시보기로 제공됩니다.
Whitehawk Therapeutics (Nasdaq: WHWK), société de thérapeutiques oncologiques spécialisée dans les traitements ADC contre le cancer, a annoncé sa participation à deux grandes conférences pour investisseurs. Le CEO Dave Lennon participera à des entretiens informels lors du Morgan Stanley Global Healthcare Conference le 8 septembre 2025 à 16h50 ET et du H.C. Wainwright Global Investment Conference le 9 septembre 2025 à 15h30 ET.
Les deux événements se tiendront à New York City et seront diffusés en direct via des webcasts accessibles sur le site IR de Whitehawk, les replays étant disponibles pendant environ 30 jours après les conférences.
Whitehawk Therapeutics (Nasdaq: WHWK), ein auf ADC-Krebsbehandlungen spezialisiertes Onkologieunternehmen, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen angekündigt. CEO Dave Lennon wird an informellen Gesprächen beim Morgan Stanley Global Healthcare Conference am 8. September 2025 um 16:50 Uhr ET und beim H.C. Wainwright Global Investment Conference am 9. September 2025 um 15:30 Uhr ET teilnehmen.
Beide Veranstaltungen finden in New York City statt und werden live per Webcast über die IR-Website von Whitehawk übertragen; Wiederholungen sind für etwa 30 Tage nach den Veranstaltungen verfügbar.
- None.
- None.
- Morgan Stanley 23rd Annual Global Healthcare Conference on Monday, September 8, 2025. Fireside chat at 4:50 PM ET.
- H.C. Wainwright 27th Annual Global Investment Conference on Tuesday, September 9, 2025. Fireside chat at 3:30 PM ET.
A live webcast of the fireside chat events can be accessed by visiting the Whitehawk Therapeutics IR website. These will be available for replay for approximately 30 days following the event.
About Whitehawk Therapeutics
Whitehawk Therapeutics is an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Whitehawk's advanced three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement. More information on the Company is available at www.whitehawktx.com and connect with us on LinkedIn.
Contact
IR@whitehawktx.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/whitehawk-therapeutics-to-participate-in-upcoming-investor-conferences-302543271.html
SOURCE Whitehawk Therapeutics, Inc.
FAQ
When is Whitehawk Therapeutics (WHWK) presenting at the Morgan Stanley Healthcare Conference 2025?
How can investors access Whitehawk Therapeutics' (WHWK) conference presentations?
What conferences is Whitehawk Therapeutics (WHWK) attending in September 2025?
Who will represent Whitehawk Therapeutics (WHWK) at the upcoming investor conferences?
